1. Introduction {#sec1-molecules-24-01059}
===============

Although immune checkpoint blockades such as anti-PD-L1 (programmed cell death-ligand 1), anti-PD-1 (programmed cell death protein 1) \[[@B1-molecules-24-01059]\], and anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) \[[@B2-molecules-24-01059]\] have demonstrated attractive therapeutic effects in multiple clinical trials, this new modality often suffers from a low response rate at least due to the immune escape developed by tumors \[[@B3-molecules-24-01059]\]. Therefore, there is great interest in developing small molecule agents capable of reversing tumor immune escape to restore the body's immune system.

Indoleamine 2,3-dioxygenase 1 (IDO-1) is a monomeric heme-containing enzyme found in nonhepatic human tissues \[[@B4-molecules-24-01059]\]. It catalyzes the oxidative cleavage of the pyrrole ring of [l]{.smallcaps}-tryptophan ([l]{.smallcaps}-Trp) in the first and rate-limiting step of the kynurenine pathway to produce *N*-formylkynurenine \[[@B5-molecules-24-01059]\]. This reaction not only leads to a local decrease of [l]{.smallcaps}-Trp concentration, but also generates a variety of catabolic products, which both account for the immunosuppressive effects of IDO-1 \[[@B6-molecules-24-01059],[@B7-molecules-24-01059],[@B8-molecules-24-01059],[@B9-molecules-24-01059]\]. Thus, IDO-1 is considered as one of the key factors in the process of immune evasion in tumor microenvironment \[[@B10-molecules-24-01059]\]. Overexpression of IDO-1 has been observed in a number of human malignancies, including ovarian, colorectal, and pancreatic cancers \[[@B11-molecules-24-01059]\]. A growing body of clinical evidence indicated that the high expression of IDO-1 in tumors is directly correlated with a low survival rate \[[@B12-molecules-24-01059]\]. In addition, IDO-1 inhibitors have demonstrated a significant cooperative effect with chemotherapy, radiotherapy, or cancer vaccines in preclinical models of cancer \[[@B13-molecules-24-01059],[@B14-molecules-24-01059],[@B15-molecules-24-01059],[@B16-molecules-24-01059]\]. Accordingly, inhibition of IDO-1 would be a very useful strategy for the treatment of cancer. In the past few years, intense efforts have been devoted to developing IDO-1 inhibitors for the immuno-oncology therapy \[[@B17-molecules-24-01059]\]. A number of structurally diverse natural products and synthetic IDO-1 inhibitors have been reported. Several IDO-1 inhibitors entered clinical trials such as indoximod (**1**) \[[@B13-molecules-24-01059],[@B18-molecules-24-01059]\], epacadostat (**2**) \[[@B3-molecules-24-01059]\], and NLG919 (**3**) ([Figure 1](#molecules-24-01059-f001){ref-type="fig"}) \[[@B19-molecules-24-01059]\]. However, none of them have been launched for clinical practice yet. Thus, the discovery of new IDO-1 inhibitors is still in great demanded.

Natural products have long served as valuable starting points for drug discovery due to their unique molecular frameworks and novel mechanisms of actions. Danshen, a well-known traditional Chinese medicine (TCM) herb derived from the dried root or rhizome of *Salvia miltiorrhiza Bunge*, has long been used in Asian countries for multiple therapeutic remedies including cardiovascular and cerebrovascular disorders as well as inflammatory diseases \[[@B20-molecules-24-01059],[@B21-molecules-24-01059],[@B22-molecules-24-01059]\]. Tanshinones such as Tan-IIA (**6**) ([Figure 1](#molecules-24-01059-f001){ref-type="fig"}), a group of lipophilic furano-*o*-naphthaquinone diterpenes isolated exclusively from this TCM herb, have demonstrated various pharmacological activities, such as cardio-protection, antibacterial, anti-inflammatory, antioxidant, anti-platelet aggregation, and anticancer properties \[[@B23-molecules-24-01059],[@B24-molecules-24-01059]\].

As part of our drug discovery program towards identification of lead compounds from natural products bearing *o*-naphthaquinone scaffold \[[@B25-molecules-24-01059],[@B26-molecules-24-01059],[@B27-molecules-24-01059],[@B28-molecules-24-01059],[@B29-molecules-24-01059],[@B30-molecules-24-01059],[@B31-molecules-24-01059]\], we screened our in-house compound library derived from *o*-naphthaquinones to pursue novel IDO-1 inhibitors, and found acyloxy derivatives of **6** possessing moderate IDO-1 inhibitory activity. When our project was ongoing, three *o*-naphthaquinone derivatives **4**, **5**, **9** were also identified as IDO-1 inhibitors by Wang and Xu et al. using machine-learning-based virtual screening ([Figure 1](#molecules-24-01059-f001){ref-type="fig"}) \[[@B32-molecules-24-01059]\]. Inspired by these results, we further performed structural optimization based on the acyloxy derivatives to explore the chemical space of *o*-naphthaquinone scaffold for IDO-1 inhibition. Herein, we disclosed our effort on the chemical synthesis, biological evaluation, and molecular docking of *o*-naphthaquinone derivatives as novel IDO-1 inhibitors.

2. Results and Discussion {#sec2-molecules-24-01059}
=========================

2.1. Chemistry {#sec2dot1-molecules-24-01059}
--------------

Following our previously established acyloxylation procedure \[[@B26-molecules-24-01059],[@B27-molecules-24-01059],[@B28-molecules-24-01059]\], a series of diverse acyloxy derivatives **7a**--**m** \[[@B27-molecules-24-01059]\] were readily accessed by action of different carboxylic acids with **6** in 45%--95% yields ([Table 1](#molecules-24-01059-t001){ref-type="table"}).

As outlined in [Scheme 1](#molecules-24-01059-sch001){ref-type="scheme"}, further hydrolysis of compound **7a** with K~2~CO~3~ in methanol afforded 1-hydroxyl product **8** \[[@B33-molecules-24-01059]\] in 99% yield, which further underwent an elimination reaction in the presence of pyridinium *p*--toluenesulfonate (PPTS) at 110 °C to give the 1-ene analogue **9** \[[@B33-molecules-24-01059]\] in 85% yield. To introduce a hydroxyl group to the 3-position of the A-ring, an allylic oxidation was performed by treatment of **9** with selenium dioxide in refluxing 1,4-dioxane/H~2~O for 1.5 h to directly produce the Δ^1^-3-ketone (1-ene-3-ketone) derivative **11** \[[@B34-molecules-24-01059],[@B35-molecules-24-01059]\] in 81% yield as sole product, instead of the 1-ene-3-hydroxyl derivative **10**. Interestingly, prolonged reaction time not only provided **11**, but also gave rise to 17-hydroxyl enone derivative **12** in 28% yield. It was believed that compounds **11** and **12** were produced by further oxidation of **10** although it was not observed in the reaction. Alternatively, reduction of **11** with NaBH~4~ provided allylic alcohol **10**. In addition, treatment of compound **8** with 2-iodoxybenzoic acid in a mixture solvent of toluene and DMSO produced 1-ketone **13** \[[@B33-molecules-24-01059]\] in 27% yield together with some minor enone derivative **14**. Further oxidation of **13** with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) could readily produce 1-ketone-Δ^2^ (1-ketone-2-ene) compound **14** in 70% yield. Subsequently, refluxing of **14** in dioxane/H~2~O using SeO~2~ as the oxidant afforded 17-hydroxy enone derivative **15** as the single product.

2.2. Biological Evaluation {#sec2dot2-molecules-24-01059}
--------------------------

All the synthesized derivatives were evaluated for their IDO-1 inhibitory activities using epacadostat as the positive control agent. The potent compounds were further assayed for their cellular activity in HEK 293 cells over-expressing human IDO-1. As shown in [Table 2](#molecules-24-01059-t002){ref-type="table"}, a series of acyloxylated derivatives **7a**--**m** was first evaluated. Compared to **6**, acyclic acyloxylated derivatives **7a**--**b** and **7e**--**f** displayed significantly improved IDO-1 inhibitory activity with IC~50~ values ranging from 2 to 8 µM. However, installation of aryl or heteroaryl group at C-15 of the furan ring (**7c**--**d**) resulted in loss of the activity with IC~50~ value greater than 20 µM. Among cyclic acyloxylated derivatives **7g**--**m**, furan compound **7k** possessed the most potent activity against IDO-1 with an IC~50~ value of 4.60 µM. Most of the six-membered cyclic acyloxylated derivatives **7h**--**i** exhibited relatively weak activity with IC~50~ values around 20 µM except pyrazine compound **7m**. Hydrolysis of the acyloxyl into the hydroxyl (compound **8**) displayed comparable inhibitory activity to that of precursor **7a**. Compound **9** with 1-ene possessed 61.2% inhibitory rate at 20 µM, which is less potent than that reported by literature \[[@B32-molecules-24-01059]\]. Compound **10** with hydroxyl group at the allylic position recovered the activity with an IC~50~ value of 3.10 µM. Compound **11** with 1-ene-3-ketone moiety exhibited significantly improved IDO-1 inhibitory activity with an IC~50~ value of 0.84 µM, and 17-hydroxyl derivative **12** also possessed more potent activity with 0.37 µM IC~50~ value. By contrast, both 1-ketone-2-ene compound **14** and its 17-hydroxyl analogue **15** demonstrated weak activities with IC~50~ values around 20 µM.

Compounds **9**--**14** were further assayed for their activity to inhibit IDO-1 in HEK 293-hIDO-1 cells. Compared to their enzymatic activity, most of them displayed less potent inhibitory activity against IDO-1 probably due to their poor permeability. Among them, compound **12** exhibited the most potent cellular inhibitory activity with an IC~50~ value of 3.85 µM. The calculated cLogP values of **11** and **12** with Chemdraw were 3.90 and 2.36, respectively, which may account for their difference on the cellular potency.

2.3. Molecular Docking Study {#sec2dot3-molecules-24-01059}
----------------------------

To understand the binding modes of our compounds for IDO-1, compounds **11**, **12**, and **14** were docked into the binding pocket of an IDO-1 X-ray crystal structure (PDB code 5WHR). All of them could interact with residues Phe226, Thr379, Phe163, Tyr126, and Gly378 within hydrophobic pockets ([Figure S17](#app1-molecules-24-01059){ref-type="app"}). The *ortho*-diketone moiety of **11** interacted with heme Fe^2+^ through two coordination bonds, and its 3-ketone had an additional hydrogen-bond interaction with Thr379 ([Figure 2](#molecules-24-01059-f002){ref-type="fig"}a). For compound **12**, the *ortho*-diketone moiety not only formed two coordination bonds with heme Fe^2+^ ([Figure 2](#molecules-24-01059-f002){ref-type="fig"}b), but also had a hydrogen-bond interaction with the NH of Ala264 ([Figure S17b](#app1-molecules-24-01059){ref-type="app"}). Besides, the 17-hydroxyl group of **12** also interacted with residue Ser167 via a hydrogen-bond ([Figure S17b](#app1-molecules-24-01059){ref-type="app"}). The 1-ketone group of **14** formed only one coordination bond with Fe^2+^ of heme ([Figure 2](#molecules-24-01059-f002){ref-type="fig"}c). These docking results suggested that compounds **12** and **11** have more interactions with IDO-1 than **14**, which may account for their more potent IDO-1 inhibitory activity.

3. Materials and Methods {#sec3-molecules-24-01059}
========================

3.1. Chemistry {#sec3dot1-molecules-24-01059}
--------------

### 3.1.1. General Chemistry {#sec3dot1dot1-molecules-24-01059}

All solvents and chemical reagents were obtained from commercial sources and used without further purifications. ^1^H- and ^13^C-NMR spectra were recorded on a Varian Mercury 400 NMR spectrometer (Varian, San Francisco, CA, USA) and Bruker avance III (Bruker, Karlsruhe, Germany). High-resolution mass spectrometry (HRMS) analysis was recorded at an ionizing voltage of 70 eV on a Agilent G6520 Q-TOF spectrometer (Agilent, San Francisco, CA, USA). Flash column chromatography on silica gel (200--300 mesh) was used for the routine purification of reaction products. All reactions were monitored by TLC on silica gel plates.

### 3.1.2. Procedure for the Preparation of Compounds {#sec3dot1dot2-molecules-24-01059}

#### Synthesis of 1,6,6-trimethyl-6,7-dihydrophenanthro\[1,2-b\]furan-10,11-dione (**9**) \[[@B33-molecules-24-01059]\]

To a solution of **8** (100 mg, 0.322 mmol) in toluene (3 mL) was added pyridinium *p*--toluenesulfonate (PPTS, 248 mg, 0.483 mmol). The reaction mixture was stirred at 110 °C for 12 h and then diluted with H~2~O and extracted with EtOAc (100 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated in vacuo. The residue was further purified by silica gel column, and elution with 15%--10% EtOAc in hexane afforded the desired product **9** (80 mg, 85%) as a red solid. ^1^H-NMR (400 MHz, CDCl~3~) δ 7.85 (dt, *J* = 10.2, 1.8 Hz, 1H), 7.55 (s, 2H), 7.23 (d, *J* = 1.3 Hz, 1H), 6.33 (dt, *J* = 10.1, 4.6 Hz, 1H), 2.29 (d, *J* = 1.8 Hz, 1H), 2.28 (d, *J* = 1.9 Hz, 1H), 2.27 (d, *J* = 1.3 Hz, 3H), 1.30 (s, 6H). ^13^C-NMR (126 MHz, CDCl~3~) δ 184.4, 175.9, 161.5, 148.5, 141.3, 137.4, 134.0, 130.3, 127.3, 124.5, 123.1, 121.5, 121.1, 120.0, 37.9, 34.2, 28.4, 8.8.

#### Synthesis of 1,6,6-trimethylphenanthro\[1,2-b\]furan-7,10,11(6*H*)-trione (**11**)

To a solution of **9** (35 mg, 0.120 mmol) in 1,4-dioxane (2 mL) was added selenium dioxide (13 mg, 0.120 mmol). The reaction mixture was stirred at 100 °C for 1.5 h and then diluted with H~2~O and extracted with EtOAc (50 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated in vacuo. The residue was further purified by silica gel column, and elution with 1% MeOH in CH~2~Cl~2~ afforded the desired product **11** (30 mg, 82%) as a red solid. m.p. 261.2--262.8 °C. ^1^H-NMR (400 MHz, CDCl~3~): δ 8.99 (d, *J* = 10.5 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 1H), 7.72 (d, *J* = 8.1 Hz, 1H), 7.30 (s, 1H), 6.41 (d, *J* = 10.5 Hz, 1H), 2.29 (s, 3H), 1.51 (s, 6H). ^13^C-NMR (126 MHz, CDCl~3~) δ 201.9, 184.2, 175.3, 160.5, 150.7, 142.0, 139.2, 132.3, 132.3, 128.6, 128.5, 125.3, 123.5, 121.5, 120.6, 47.9, 27.6, 8.8. MS (ESI, \[M + Na\]^+^) *m*/*z* 329.3. HRMS (ESI, \[M + H\]^+^) calcd for C~19~H~15~O~4~, 307.0965; found, 307.0973.

#### Synthesis of 1-(hydroxymethyl)-6,6-dimethylphenanthro\[1,2-b\]furan-7,10,11(6*H*)-trione (**12**)

To a solution of **9** (80 mg, 0.273 mmol) in 1,4-dioxane (2 mL) was added selenium dioxide (30 mg, 0.273 mmol). The reaction mixture was stirred at 100 °C for 24 h and then diluted with H~2~O and extracted with EtOAc (100 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated in vacuo. The residue was further purified by silica gel column, and elution with 1%--5% MeOH in CH~2~Cl~2~ afforded the desired product **11** (30 mg, 36%, Rf = 0.4 in 5% MeOH/CH~2~Cl~2~) and **12** (25 mg, 28%, Rf = 0.2 in 5% MeOH/CH~2~Cl~2~) as red solid. Compound **12**: m.p. 213.4-216.5 °C. ^1^H-NMR (400 MHz, CDCl~3~) δ 8.99 (d, *J* = 10.5 Hz, 1H), 7.83 (d, *J* = 8.1 Hz, 1H), 7.75 (d, *J* = 8.3 Hz, 1H), 7.48 (s, 1H), 6.44 (d, *J* = 10.5 Hz, 1H), 4.71 (s, 2H), 1.52 (s, 6H). ^13^C-NMR (126 MHz, CDCl~3~) δ 201.6, 183.3, 175.5, 161.9, 151.6, 141.4, 138.8, 132.8, 132.5, 129.0, 128.0, 126.1, 125.2, 123.8, 120.1, 55.2, 48.1, 27.6. MS (ESI, \[M + Na\]^+^) *m*/*z* 345.2. HRMS (ESI, \[M + H\]^+^) calcd for C~19~H~15~O~5~, 323.0914; found, 323.0915.

#### Synthesis of 7-hydroxy-1,6,6-trimethyl-6,7-dihydrophenanthro\[1,2-b\]furan-10,11-dione (**10**) \[[@B33-molecules-24-01059]\]

To a solution of **11** (30 mg, 0.098 mmol) in MeOH (2 mL) was added NaBH~4~ (11 mg, 0.300 mmol). The reaction mixture was stirred at rt for 1 h and then evaporated the solvent, diluted with H~2~O, and extracted with EtOAc (50 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated in vacuo. The residue was further purified by silica gel column, and elution with 1%--2% MeOH in CH~2~Cl~2~ afforded the desired product **10** (27 mg, 90%) as a red solid. m.p. 185.2-188.5 °C. ^1^H-NMR (400 MHz, CDCl~3~) δ 7.87 (d, *J* = 10.2 Hz, 1H), 7.64--7.55 (m, 2H), 7.24 (s, 1H), 6.39 (dd, *J* = 10.2, 4.4 Hz, 1H), 4.08 (d, *J* = 4.5 Hz, 1H), 2.26 (s, 3H), 1.39 (s, 3H), 1.28 (s, 3H). ^13^C-NMR (126 MHz, CDCl~3~) δ 184.2, 175.6, 161.2, 147.1, 141.5, 135.8, 135.5, 131.5, 127.7, 125.0, 123.6, 122.1, 121.2, 120.2, 72.5, 40.0, 26.3, 21.9, 8.8.

#### Synthesis of 1,6,6-trimethyl-7,8-dihydrophenanthro\[1,2-b\]furan-9,10,11(6*H*)-trione (**13**) and 1,6,6-trimethylphenanthro\[1,2-b\]furan-9,10,11(6*H*)-trione (**14**)

To a solution of **8** (200 mg, 0.644 mmol) in toluene (4 mL) and DMSO (2 mL) was added 2-Iodoxybenzoic acid (1.082 g, 3.864 mmol). The reaction mixture was stirred at 60 °C microwave for 3 h and then diluted with H~2~O and extracted with EtOAc (150 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated in vacuo. The residue was further purified by silica gel column, and elution with 30%--40% EtOAc in hexane afforded **13** (55 mg, 27%, Rf = 0.4 in 40% EtOAc/hexane) and **14** (38 mg, 19%, Rf = 0.2 in 40% EtOAc/hexane) as an orange solid. Compound **13**: ^1^H-NMR (300 MHz, CDCl~3~) δ 7.72 (d, *J* = 8.2 Hz, 1H), 7.57 (d, *J* = 8.2 Hz, 1H), 7.26 (d, *J* = 1.4 Hz, 1H), 2.92 (t, *J* = 7.2 Hz, 2H), 2.26 (d, *J* = 1.3 Hz, 3H), 2.07 (t, *J* = 7.2 Hz, 2H), 1.34 (s, 6H). Compound **14**: m.p. 158.3--160.8 °C.^1^H-NMR (400 MHz, CDCl~3~) δ 7.81 (d, *J* = 8.3 Hz, 1H), 7.72 (d, *J* = 8.3 Hz, 1H), 7.27 (s, 1H), 6.80 (d, *J* = 10.2 Hz, 1H), 6.48 (d, *J* = 10.2 Hz, 1H), 2.26 (s, 3H), 1.50 (s, 6H). ^13^C-NMR (126 MHz, CDCl~3~) δ 185.8, 183.4, 179.3, 159.6, 154.6, 151.8, 141.9, 135.3, 132.8, 131.6, 128.9, 127.4, 124.5, 121.3, 120.9, 38.3, 29.4, 8.7. MS (ESI, \[M + H\]^+^) *m*/*z* 307.4. HRMS (ESI) calcd for C~19~H~15~O~4~, 307.0965; found, 307.0967.

#### Synthesis of 1,6,6-trimethylphenanthro\[1,2-b\]furan-9,10,11(6*H*)-trione (**14**)

To a solution of **13** (44 mg, 0.14 mmol) in toluene (3 mL) was added 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 49 mg, 0.21 mmol). The reaction mixture was stirred at 80 °C for 36 h and then diluted with H~2~O and extracted with EtOAc (100 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated in vacuo. The residue was further purified by silica gel column, and elution with 40% EtOAc in hexane afforded **14** (31 mg, 70%).

#### Synthesis of 1-(hydroxymethyl)-6,6-dimethylphenanthro\[1,2-b\]furan-9,10,11(6*H*)-trione (**15**)

To a solution of **14** (30 mg, 0.098 mmol) in 1,4-dioxane (2 mL) was added selenium dioxide (44 mg, 0.392 mmol). The reaction mixture was stirred at 100 °C for 36 h and then diluted with H~2~O and extracted with EtOAc (50 mL × 3). The combined organic layer was washed with brine, dried over anhydrous Na~2~SO~4~, and concentrated in vacuo. The residue was further purified by silica gel column, and elution with 1%--2% MeOH in CH~2~Cl~2~ afforded the desired product **15** (5 mg, 16%) as an orange solid. m.p. 195.5--198.4 °C. ^1^H-NMR (400 MHz, CDCl~3~) δ 7.85 (d, *J* = 8.3 Hz, 1H), 7.75 (d, *J* = 8.3 Hz, 1H), 7.45 (s, 1H), 6.82 (d, *J* = 10.3 Hz, 1H), 6.47 (d, *J* = 10.2 Hz, 1H), 4.69 (s, 2H), 1.51 (s, 6H). ^13^C-NMR (126 MHz, CDCl~3~) δ 184.7, 183.3, 179.4, 161.1, 154.6, 152.5, 141.2, 135.7, 132.8, 131.8, 128.5, 127.4, 126.1, 124.7, 120.5, 55.2, 38.4, 29.5. HRMS (ESI, \[M + H\]^+^) calcd for C~19~H~15~O~5~, 323.0914; found, 323.0901.

3.2. Biology {#sec3dot2-molecules-24-01059}
------------

hIDO-1 enzymatic assay. The hIDO-1 enzymatic assay was performed as described previously \[[@B36-molecules-24-01059]\]. Briefly, a standard reaction mixture (30 μL) containing 100 mM potassium phosphate buffer (pH 6.5), 40 mmol/L ascorbic acid and 0.01% Triton X-100, 200 µg/mL catalase, 20 µmol/L methylene blue, and 0.05 µM rhIDO-1 was added to the solution (60 μL) containing the substrate [l]{.smallcaps}-tryptophan (250 µmol/L) and the test sample at a determined concentration. The reaction was carried out at 37 °C for 30 min and stopped by adding 45 µL of 30% (*w*/*v*) trichloroacetic acid. After being heated at 65 °C for 15 min, the reaction mixture was centrifuged at 12,000 rpm for 10 min. The supernatant (100 µL) was transferred into a well of a 96-well microplate and mixed with 100 µL of 2% (*w*/*v*) p-dimethylaminobenzaldehyde in acetic acid. The yellow pigment derived from kynurenine was measured at 492 nm using a Spectra Max Plus 384 microplate reader (Molecular Devices, Sunnyvale, CA, USA). IC~50~ values were calculated by using Graph Pad Prism 6 software (version 6.00, Graph Pad Software, San Diego, CA, USA).

Cell-based assay of IDO-1 activity. The cellular activity of IDO-1 was detected as described previously \[[@B36-molecules-24-01059]\]. HEK 293 cells were seeded in a 6-well culture plate at a density of 5 × 10^5^ cells/well and cultured overnight. After 24 h, HEK 293 cells were transfected with pcDNA3.1-hIDO-1 using Lipofectamine 2000 according to the manufacturer's instructions. Cells were seeded in a 96-well culture plate at a density of 2.5 × 10^4^ cells/well 24 h after transfection. A serial dilution of the tested compounds in 10 µL PBS was added to the cells. After an additional 12-h incubation, 200 µL of the supernatant per well was transferred to a new 96-well plate and mixed with 100 µL of 30% trichloroacetic acid in each well, and the plate was incubated at 65 °C for 15 min to hydrolyze *N*-formylkynurenine produced by the catalytic reaction of hIDO-1. The reaction mixture was then centrifuged for 10 min at 12,000 rpm to remove the sediments. Then, 100 µL of the supernatant per well were transferred to another 96-well plate and mixed with 100 µL of 2% (*w*/*v*) *p*-dimethylaminobenzaldehyde in acetic acid. The yellow color derived from kynurenine was measured at 492 nm using a Spectra Max Plus 384 microplate reader (Molecular Devices, Sunnyvale, CA, USA). IC~50~ values were calculated by using Graph Pad Prism 6 software (version 6.00, Graph Pad Software, San Diego, CA, USA).

3.3. Docking Study {#sec3dot3-molecules-24-01059}
------------------

Molecular modeling study of our compounds against IDO-1 was performed using the Schrödinger Suite 2015-4 (Schrödinger, LLC, New York, NY, USA). The X-ray crystal structure of IDO-1 was obtained from the Protein Data Bank. The IDO-1 protein preparation was revised using Protein Preparation Wizard. The receptor grid box was generated 25 × 25 × 25 Å cubic size. The compound was minimized using an OPLS_2005 force field with a dielectric constant value 80.0 in Macro Model.

4. Conclusions {#sec4-molecules-24-01059}
==============

In conclusion, we have designed and synthesized a series of furano-*o*-naphthaquinone derivatives as novel IDO-1 inhibitors. Among them, 1-ene-3-ketone-17-hydroxyl derivative **12** exhibited significantly improved enzymatic and cellular inhibitory activity against IDO-1 when compared to acyloxy derivatives. Besides, the molecular docking study also disclosed compounds **12** and **11** have more interactions with the binding pocket of IDO-1 via hydrogen-bond, which may account for their higher IDO-1 inhibitory activity. Although our synthesized derivatives displayed relative lower inhibitory activity than reported IDO-1 inhibitors, the *o*-naphthaquinone scaffold together with the novel binding model will open new avenues to develop better IDO-1 inhibitors for the immuno-oncology therapy.

**Sample Availability:** Samples of the compounds **11**, **12**, **14** are available from the authors.
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![Structures of known and our reported indoleamine 2,3-dioxygenase 1 (IDO-1) Inhibitors.](molecules-24-01059-g001){#molecules-24-01059-f001}

![Synthesis of *o*-naphthaquinone derivatives **11**--**15**. Reagents and conditions: (**a**) PPTS, toluene, 110 °C, 12 h; (**b**) SeO~2~, 1,4-dioxane, 100 °C; (**c**) NaBH~4~, MeOH, rt; (**d**) IBX, toluene/DMSO = 4:2, 60 °C, microwave, 3 h; (**e**) DDQ, toluene, 80 °C, 72 h; (**f**) SeO~2~, 1,4-dioxane, 100 °C, 36 h.](molecules-24-01059-sch001){#molecules-24-01059-sch001}

![Docking models of compounds **11**, **12,** and **14** bound to IDO-1. (**a**) Computational modeling at the active site of IDO-1 for **11**; (**b**) computational modeling at the active site of IDO-1 for **12**; (**c**) computational modeling at the active site of IDO-1 for **14**.](molecules-24-01059-g002){#molecules-24-01059-f002}
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###### 

Structures of acyloxy derivatives **7a**--**m**.

  Compound Number   R^1^                               R^2^                               Compound Number   R^1^                               R^2^
  ----------------- ---------------------------------- ---------------------------------- ----------------- ---------------------------------- ------
  **7a**            ![](molecules-24-01059-i001.jpg)   H                                  **7h**            ![](molecules-24-01059-i002.jpg)   H
  **7b**            ![](molecules-24-01059-i003.jpg)   H                                  **7i**            ![](molecules-24-01059-i004.jpg)   H
  **7c**            ![](molecules-24-01059-i005.jpg)   ![](molecules-24-01059-i006.jpg)   **7j**            ![](molecules-24-01059-i007.jpg)   H
  **7d**            ![](molecules-24-01059-i008.jpg)   ![](molecules-24-01059-i009.jpg)   **7k**            ![](molecules-24-01059-i010.jpg)   H
  **7e**            ![](molecules-24-01059-i011.jpg)   H                                  **7l**            ![](molecules-24-01059-i012.jpg)   H
  **7f**            ![](molecules-24-01059-i013.jpg)   H                                  **7m**            ![](molecules-24-01059-i014.jpg)   H
  **7g**            ![](molecules-24-01059-i015.jpg)   H                                                                                       

molecules-24-01059-t002_Table 2

###### 

The IDO-1 inhibitory activity of *o*-naphthaquinone derivatives in enzyme- and cell-based assays.

  Compound Number                    R^1^                               R^2^                               Enzymatic IC~50~ (μM) or Inhibitory Rate at 20 µM ^a^   Cellular IC~50~ (μM) ^a^   
  ---------------------------------- ---------------------------------- ---------------------------------- ------------------------------------------------------- -------------------------- ---------------
  ![](molecules-24-01059-i016.jpg)   **6**                              H                                  H                                                       23.1 ± 1.6%                --- ^b^
  **7a**                             ![](molecules-24-01059-i017.jpg)   H                                  3.72 ± 0.45                                             ---                        
  **7b**                             ![](molecules-24-01059-i018.jpg)   H                                  4.72 ± 0.30                                             ---                        
  **7c**                             ![](molecules-24-01059-i019.jpg)   ![](molecules-24-01059-i020.jpg)   29.3 ± 2.2%                                             ---                        
  **7d**                             ![](molecules-24-01059-i021.jpg)   ![](molecules-24-01059-i022.jpg)   21.5 ± 1.1%                                             ---                        
  **7e**                             ![](molecules-24-01059-i023.jpg)   H                                  7.47 ± 3.58                                             ---                        
  **7f**                             ![](molecules-24-01059-i024.jpg)   H                                  2.74 ± 0.10                                             ---                        
  **7g**                             ![](molecules-24-01059-i025.jpg)   H                                  7.05 ± 2.46                                             ---                        
  **7h**                             ![](molecules-24-01059-i026.jpg)   H                                  48.0 ± 3.2%                                             ---                        
  **7i**                             ![](molecules-24-01059-i027.jpg)   H                                  54.5 ± 2.3%                                             ---                        
  **7j**                             ![](molecules-24-01059-i028.jpg)   H                                  60.4 ± 3.9%                                             ---                        
  **7k**                             ![](molecules-24-01059-i029.jpg)   H                                  4.60 ± 2.81                                             ---                        
  **7l**                             ![](molecules-24-01059-i030.jpg)   H                                  5.71 ± 0.47                                             ---                        
  **7m**                             ![](molecules-24-01059-i031.jpg)   H                                  4.96 ± 2.02                                             ---                        
  **8**                              OH                                 H                                  2.83 ± 0.12                                             ---                        
  ![](molecules-24-01059-i032.jpg)   **9**                              H                                                                                          61.2 ± 2.1%                \>10
  **10**                             OH                                                                    3.10 ± 1.02                                             \>10                       
  ![](molecules-24-01059-i033.jpg)   **11**                             H                                                                                          0.84 ± 0.26                \>10
  **12**                             OH                                                                    0.37 ± 0.02                                             3.85 ± 0.86                
  ![](molecules-24-01059-i034.jpg)   **14**                             H                                                                                          52.7 ± 2.5%                \>10
  **15**                             OH                                                                    68.0 ± 8.6%                                             ---                        
  Epacadostat                                                                                                                                                      0.086 ± 0.009              0.023 ± 0.003

^a^ The values are the mean ± SE of two independent experiments; ^b^ Not determined.

[^1]: These authors contributed equally to this work.
